Celldex (CLDX) Initiates Phase II Study On Cancer Candidate

By Zacks Investment ResearchStock MarketsNov 19, 2017 09:33PM ET

www.investing.com/analysis/celldex-cldx-initiates-phase-ii-study-on-cancer-candidate-200266712

Celldex (CLDX) Initiates Phase II Study On Cancer Candidate

By Zacks Investment Research | Nov 19, 2017 09:33PM ET

Saved. See Saved Items.

This article has already been saved in your Saved Items

LLY

+1.25%

Add to/Remove from Watchlist

MRK

+0.40%

Add to/Remove from Watchlist

AMZN

+2.68%

Add to/Remove from Watchlist

BMY

+1.18%

Add to/Remove from Watchlist

CLDX

+7.50%

Add to/Remove from Watchlist

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the initiation of a phase II study on its human monoclonal antibody, CDX-3379 in patients with advanced head and neck squamous cell carcinoma ("HNSCC").

With no approved products in its portfolio, investor focus remains on the progress of Celldex’s pipeline candidates.

Shares of the company were up more than 2% on Friday following the news. However, Celldex’s shares were down 17.8% so far this year, underperforming the industry’s gain of 1.5% in that period.

The phase II study will evaluate CDX-3379 in combination with Eli Lilly’s (NYSE:LLY) Erbitux in patients with advanced HNSCC who are Erbitux resistant and previously treated with an anti-PD1 checkpoint inhibitorThe company believes that the patient population being evaluated in the study has limited availability of treatment options and a particularly poor prognosis. The study will continue the treatment till progression of the disease starts or patients become intolerant to the combination therapy. The primary objective of the study is to achieve objective response rate.

The two-stage study will enroll 13 patients in the first stage and initiate the second stage upon achieving partial or complete response in at least one patient.

We remind investors that a completed phase Ib study on the combination therapy had shown promising anti-tumor activity in HSNCC patients including a durable complete response in a single patient whose disease had progressed on Erbitux monotherapy.

Celldex is also progressing well with its lead pipeline candidate, glembatumumab vedotin, which is being evaluated in a phase IIb study in patients with triple negative breast cancer and in a phase II study in melanoma patients. The company is also evaluating the candidate in combination with Bristol-Myers’s (NYSE:BMY) Opdivo or Merck’s (NYSE:MRK) Keytruda in two separate cohorts in its melanoma study.

Celldex Therapeutics, Inc. Price

Celldex Therapeutics, Inc. Price | Celldex Therapeutics, Inc. Quote

Celldex currently holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Eli Lilly and Company (LLY): Free Stock Analysis Report

Merck & Company, Inc. (MRK): Free Stock Analysis Report

Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report

Original post

Zacks Investment Research

3 Safe-Haven Stocks to Buy Amidst a Global Trade War By Jesse Cohen - Mar 05, 2025 5

These stocks provide a compelling case as safe-haven stocks in the face of an escalating trade war. Each company operates within sectors that are relatively resilient to economic...

What Stagflation Means for Investors and These Stocks By Gabriel Osorio-Mazzilli - Mar 05, 2025

When the market narrative becomes too widely accepted, excess seems to be created in some areas of the economy as businesses prepare for what’s coming their way. Today’s stock...

S&P 500: All Eyes on 200-Day MA - Holding This Level Could Spark... By Fawad Razaqzada - Mar 05, 2025 5

Markets are bouncing back as investors bet on technical support, tariff relief, and Germany’s stimulus plans. But with ISM and NFP data ahead, Fed rate cut bets could shift,...

Add a Comment

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:

Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.
Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I have read Investing.com's comments guidelines and agree to the terms described.

I Agree

Write your thoughts here

Are you sure you want to delete this chart?

Delete Cancel

Post

Post also to:

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

<div id="comment">
				<div class="comment js-comment" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
    <div class="mainComment js-content">
       <div class="commentInnerWrapper">
        <a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody">
                					<span class="commentUsername">
                    	<a href="{userLink}" class="js-user-link js-user-name">{username}</a>
					</span>
                                <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
                <div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>
                 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div>             </div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="commentBigChart js-comment-chart" onclick="openViewChartPopup('{commentID}')">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
	   </div>
	</div>
	</div>			</div>
			<div id="reply">
				
    <div class="commentReply js-comment js-comment-reply" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
		<div class="commentInnerWrapper"><a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody js-content">
            				<span class="commentUsername">
					<a href="{userLink}" class="commentUsername js-user-link js-user-name" onMouseOver="">{username}</a>
				</span>
                        <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
			 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div> 			<div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

</div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="replyBigChart displayNone js-comment-chart">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
				<span id="commentSmallChart{commentID}" class="commentSmallChart pointer js-comment-chart" onclick="openViewChartPopup('{commentID}')">
                    <img src="https://d1-invdn-com.investing.com/comments_images/{commentImageSmall}" width="116" height="52" alt="{commentAlt}">
                    <span class="chartMagnifyOverlay displayNone"></span>
                    <span class="searchGlassIcon chartMagnify displayNone"></span>
                </span>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

Are you sure you want to delete this chart?

Delete Cancel

Post

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

I feel that this comment is:

Spam

Offensive

Thank You!

Your report has been sent to our moderators for review

Central Banks

Interest Rates

Next Meeting

FED

4.50%

Mar 19, 2025

ECB

2.90%

Mar 06, 2025

BOE

4.50%

Mar 20, 2025

SNB

0.50%

Mar 20, 2025

RBA

4.10%

Apr 01, 2025

BOC

3.00%

Mar 12, 2025

RBNZ

3.75%

Apr 09, 2025

BOJ

0.50%

Mar 19, 2025

CBR

21.00%

Mar 21, 2025

RBI

6.25%

Mar 10, 2025

PBOC

3.10%

BCB

13.25%

Mar 19, 2025

US 30	43,061.3	+539.6	+1.27%
US 500	5,846.7	+68.5	+1.19%
Dow Jones	43,058.63	+537.64	+1.26%
S&P 500	5,847.56	+69.38	+1.20%
Nasdaq	18,558.27	+273.10	+1.49%
S&P 500 VIX	21.96	-1.55	-6.59%
Dollar Index	104.375	-1.312	-1.24%

Crude Oil WTI	66.22	-2.04	-2.99%
Brent Oil	69.24	-1.80	-2.53%
Natural Gas	4.431	+0.081	+1.86%
Gold	2,926.79	+6.19	+0.21%
Silver	33.193	+0.812	+2.51%
Copper	4.8090	+0.2525	+5.54%
US Soybeans	1,012.38	+13.38	+1.34%

U.S. 10Y	4.280	+0.070	+1.66%
U.S. 30Y	4.573	+0.057	+1.26%
U.S. 5Y	4.065	+0.063	+1.57%
U.S. 3M	4.314	+0.010	+0.23%
US 10Y T-Note	110.77	-0.45	-0.41%
Euro Bund	127.93	-1.89	-1.46%
10-2 Yield Spread	25.61	+5.69	+28.56%

Apple	236.16	+0.23	+0.10%
NVIDIA	117.63	+1.64	+1.41%
Alphabet A	173.12	+2.20	+1.29%
Tesla	277.97	+5.93	+2.18%
Amazon.com	209.27	+5.47	+2.68%
Netflix	990.97	+18.39	+1.89%
Meta Platforms	656.90	+16.90	+2.64%

Celldex (CLDX) Initiates Phase II Study On Cancer Candidate

Related Articles